Trial · NCT04036253
Results by group40
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 40
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Efficacy Evaluation Through Change in Hemoglobin Levels | Eprex/Erypo | Baseline hemoglobin levels | 9.56 | Standard Deviation 0.60 | Hemoglobin levels (g/dL) |
| Efficacy Evaluation Through Change in Hemoglobin Levels | Hemax PFS | Baseline hemoglobin levels | 9.44 | Standard Deviation 0.81 | Hemoglobin levels (g/dL) |
| Efficacy Evaluation Through Change in Hemoglobin Levels | Eprex/Erypo | Average hemoglobin levels between visits 8 and 12 | 11.05 | Standard Deviation 0.74 | Hemoglobin levels (g/dL) |
| Efficacy Evaluation Through Change in Hemoglobin Levels | Hemax PFS | Average hemoglobin levels between visits 8 and 12 | 11.11 | Standard Deviation 1.11 | Hemoglobin levels (g/dL) |
| Efficacy Evaluation Through Change in Hemoglobin Levels | Eprex/Erypo | Hemoglobin levels change between both times | 1.49 | Standard Deviation 0.99 | Hemoglobin levels (g/dL) |
| Efficacy Evaluation Through Change in Hemoglobin Levels | Hemax PFS | Hemoglobin levels change between both times | 1.66 | Standard Deviation 1.05 | Hemoglobin levels (g/dL) |
| Adverse Events and Adverse Reactions (Safety and Tolerability) at Weeks 12 and 24. | Eprex/Erypo | Overall Adverse Events | 23 | Adverse Events | |
| Adverse Events and Adverse Reactions (Safety and Tolerability) at Weeks 12 and 24. | Hemax PFS | Overall Adverse Events | 30 | Adverse Events | |
| Adverse Events and Adverse Reactions (Safety and Tolerability) at Weeks 12 and 24. | Eprex/Erypo | Serious Events | 4 | Adverse Events | |
| Adverse Events and Adverse Reactions (Safety and Tolerability) at Weeks 12 and 24. | Hemax PFS | Serious Events | 4 | Adverse Events | |
| Percentage of Responder Patients | Eprex/Erypo | Non-Responders | 5.56 | percentage of participants | |
| Percentage of Responder Patients | Hemax PFS | Non-Responders | 4.55 | percentage of participants | |
| Percentage of Responder Patients | Eprex/Erypo | Responders | 94.44 | percentage of participants | |
| Percentage of Responder Patients | Hemax PFS | Responders | 95.45 | percentage of participants | |
| Percentage of Patients That Required Any Transfusion | Eprex/Erypo | 5 | Percentage of patients | ||
| Percentage of Patients That Required Any Transfusion | Hemax PFS | 0 | Percentage of patients | ||
| Change of Hemoglobin Level at Week 12 of Treatment | Eprex/Erypo | Baseline | 9.56 | Standard Deviation 0.60 | Hemoglobin levels (g/dL) |
| Change of Hemoglobin Level at Week 12 of Treatment | Hemax PFS | Baseline | 9.44 | Standard Deviation 0.81 | Hemoglobin levels (g/dL) |
| Change of Hemoglobin Level at Week 12 of Treatment | Eprex/Erypo | Week 8 to 12 | 11.05 | Standard Deviation 0.74 | Hemoglobin levels (g/dL) |
| Change of Hemoglobin Level at Week 12 of Treatment | Hemax PFS | Week 8 to 12 | 11.11 | Standard Deviation 1.11 | Hemoglobin levels (g/dL) |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04036253/results